The expression of p‐PI3K and p‐AKT in SCLC tumours was remarkably decreased following apatinib treatment, suggesting that apatinib may inhibit SCLC tumour growth by inhibiting the PI3K/AKT signalling pathway. This evidence concerns the gene AKT1 and neoplasm.